Financial Performance - Revenue for the year ending December 31, 2025, was $174,000, a decrease of 97.9% compared to $8,131,000 for the year ending December 31, 2024[3]. - The company reported a net loss of $17,875,000 for the year ending December 31, 2025, which is an increase of 16.8% from a net loss of $15,303,000 in the previous year[3]. - The cost of sales for 2025 was $1,091,000, down from $1,992,000 in 2024, resulting in a gross loss of $917,000[17]. - The company reported a total comprehensive loss of $16,605,000 in 2025, slightly higher than the $16,129,000 reported in 2024[18]. - The company's revenue for 2025 was $174,000, a significant decrease from $8,131,000 in 2024, primarily due to customer returns totaling $5,893,000[26]. - The company incurred a loss of $17,875,000 in 2025, compared to a loss of $15,303,000 in 2024[44]. - The company reported a basic loss per share of $0.0370 for 2025, based on a weighted average of 483,759,463 shares outstanding[43]. - The adjusted net loss for the year ended December 31, 2025, was $(16.9) million, compared to $(15.1) million in 2024[112]. Product Development and Approvals - The core product BroncAblate® received approval from the NMPA for commercialization in China, marking a significant advancement in lung cancer treatment technology[4]. - InterVapor® has been successfully launched in nearly 30 provinces/cities in China, demonstrating effective treatment for severe COPD[5]. - As of December 31, 2025, BroncAblate® has been applied in over 200 surgeries across more than 30 hospitals in China[6]. - The company holds 94 registration certificates as of December 31, 2025, including 20 NMPA certificates, 4 CE certificates, and 7 FDA certificates[14]. - Clinical trials for BroncTarget® are ongoing, with 116 subjects enrolled across 28 hospitals as of December 31, 2025[9]. - The company has developed a comprehensive interventional respiratory disease treatment platform, integrating navigation, diagnosis, and treatment[52]. - BroncTarget® is the first domestically developed targeted radiofrequency ablation system in China, currently undergoing confirmatory clinical trials[63]. - The BroncAblate® system has been approved for use in over 30 hospitals, completing nearly 200 procedures as of December 31, 2025[61]. - InterVapor® has received CE and NMPA certifications, allowing commercialization in multiple regions including Europe, China, and Australia[65]. Strategic Partnerships and Market Expansion - The company is pursuing strategic partnerships and industry acquisitions to explore further development potential[13]. - The company entered into a share subscription agreement with Shanghai Yingtai Medical Co., Ltd. and Hangzhou Linping National Capital Investment Co., Ltd. to enhance product commercialization channels[15]. - The acquisition of 157,800 shares of Valgen Holding Corporation aims to establish a comprehensive diagnostic and treatment platform for cardiopulmonary diseases[15]. - The company has designated Customer A as the exclusive domestic distributor for its medical devices in China, aiming to strengthen market presence amid regulatory changes[26]. - The company is committed to deepening its partnership with Customer A, leveraging their strong distribution capabilities in Chinese hospitals[26]. - The company is expanding its market presence, with BroncAblate® achieving listing approval in Hong Kong and ongoing registrations in other countries[62]. Research and Development - The company’s R&D expenses decreased to $7,772,000 in 2025 from $11,471,000 in 2024, a reduction of 32.5%[17]. - Research and development costs for 2025 were $7,772,000, down from $11,471,000 in 2024, indicating a strategic shift in R&D investment[33]. - Employee costs accounted for 47.9% of total R&D expenses in 2025, down from 49.5% in 2024, totaling $3.7 million[102]. Operational Metrics - Total assets less current liabilities decreased to $150,209,000 in 2025 from $169,477,000 in 2024, a decline of 11.4%[20]. - The company’s cash and cash equivalents decreased to $31,697,000 in 2025 from $46,473,000 in 2024, a decline of 31.8%[19]. - The total trade receivables decreased to $6,083,000 in 2025 from $10,344,000 in 2024, with a net amount of $3,180,000 after impairment[46]. - The company has maintained a total of 191 employees, with 170 based in China and 21 overseas[125]. Awards and Recognition - The company received multiple industry awards in 2025, enhancing its brand recognition and influence in the minimally invasive treatment of pulmonary diseases[16]. - The BRONC-RFII study results were published in the journal Respirology, highlighting the safety and efficacy of the BroncAblate® system[59]. - InterVapor® has been recognized as a "Breakthrough Device" by the FDA and is included in the GOLD guidelines for COPD treatment[64]. Corporate Governance and Compliance - The company has complied with all applicable corporate governance codes during the reporting period, with one exception regarding the separation of the roles of Chairman and CEO[118]. - The audit committee reviewed the annual consolidated financial statements and found them compliant with applicable accounting standards and regulations[126]. - There were no significant lawsuits or arbitrations involving the company during the reporting period[124]. Future Plans and Projections - The expected revenue to be recognized from remaining performance obligations is $821,000 for 2025, an increase from $586,000 in 2024[32]. - The company plans to allocate HKD 194.0 million for mergers, investments, or acquisitions of new product lines, with full utilization expected by 2030[137]. - The company plans to hold its annual general meeting on May 14, 2026[139].

Broncus Holding Corporation 進一步收購事項 香港交易及結算所有限公司及香港聯合交易所有限公司對本公告之內容概不負責，對其準確性 或完整性亦不發表任何聲明，並明確表示，概不對因本公告全部或任何部分內容而產生或因倚 賴該等內容而引致之任何損失承擔任何責任。 堃 博 醫 療 控股有限公司 （於開曼群島註冊成立的有限公司） （股份代號：2216） 主要交易 進一步收購目標公司的目標股份 及 更改所得款項淨額用途 於2026年3月21日，買方（本公司的全資附屬公司）與賣方訂立股份轉讓協議， 據此，賣方有條件同意出售，而買方有條件同意購買目標股份（佔目標公司截 至本公告日期按全面攤薄及轉換基準計算的發行在外股份的3.85%），總代價為 55,120,192美元（相等於約428.56百萬港元）。 上市規則的涵義 由於過往收購事項乃於進一步收購事項的12個月期間內進行或與其相關（兩者均 涉及收購同一家公司的股權），因此，根據上市規則第14.22條，進一步收購事 項須與過往收購事項合併計算作為一系列交易。由於與進一步收購事項相關的 其中一項或多於一項適用百分比率（定義見上市規則第14.04(9)條） ...

堃 博醫療控股有限公司 香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不負責，對其準確性 或完整性亦不發表任何聲明，並明確表示，概不就因本公告全部或任何部分內容而產生或因依 賴該等內容而引致的任何損失承擔任何責任。 Broncus Holding Corporation 承董事會命 堃博醫療控股有限公司 董事長 徐宏 香港，2026年3月19日 於本公告日期，董事會包括執行董事徐宏先生、非執行董事張奧先生及鄺豔紅女 士，以及獨立非執行董事甘博文博士、黃依倩女士及David Scott Lim醫生。 （於開曼群島註冊成立的有限公司） （股份代號：2216） 董事會會議召開日期 堃博醫療控股有限公司（「本公司」）董事（「董事」）會（「董事會」）謹此宣佈，董事 會會議將於2026年3月31日（星期二）舉行，藉以（其中包括）考慮及批准本公司及 其附屬公司截至2025年12月31日止年度之經審核全年業績及其刊發，以及考慮派 發末期股息之建議（如有）。 ...

香港交易及結算所有限公司及香港聯合交易所有限公司對本公告之內容概不負責，對其準確性 或完整性亦不發表任何聲明，並明確表示，概不對因本公告全部或任何部分內容而產生或因倚 賴該等內容而引致之任何損失承擔任何責任。 Broncus Holding Corporation 補充公告 須予披露交易 收購目標公司的目標股份 茲提述本公司日期為2025年12月29日有關收購目標公司1.05%發行在外股份的須 予披露交易的公告（「公告」）。除另有界定者外，本公告所用詞彙與前述公告所界 定者具有相同涵義。 本公司謹此向股東及潛在投資者提供前述公告的補充資料。 收購事項的理由 董事會已考慮及一直探討不同方式，以期有效將本集團產品商業化，從而提升本 集團的財務狀況。通過訂立股份轉讓協議（並於完成後成為Valgen股東協議的訂 約方），本集團將能與目標公司及其管理層進一步溝通，從而更深入了解其營運。 儘管本集團僅為目標公司的少數股東，惟本集團認為該項投資將促進雙方日後進 一步的策略合作。 本公司已考慮目標公司的研發能力、其所提供的解決方案及產品，以及訂約雙方 之間潛在的協同效應及合作，詳情載於下文：- (a) 本公司導航技術在結構性 ...

公司名稱: 堃博医疗控股有限公司 呈交日期: 2026年3月5日 I. 法定/註冊股本變動 | 1. 股份分類 | 普通股 | 股份類別 | 不適用 | | 於香港聯交所上市 (註1) | | 是 | | | | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | | 證券代號 (如上市) | 02216 | 說明 | | | | | | | | | | | 法定/註冊股份數目 | | | 面值 | | | 法定/註冊股本 | | | 上月底結存 | | | 2,000,000,000 | USD | | 0.000025 | USD | | 50,000 | | 增加 / 減少 (-) | | | 0 | | | | USD | | 0 | | 本月底結存 | | | 2,000,000,000 | USD | | 0.000025 | USD | | 50,000 | 本月底法定/註冊股本總額： USD 50,000 FF301 第 1 頁 共 10 頁 v 1.2.0 股份發行人及根據《上市規則》第十九B章上市的香港預託證券發行人的證券 ...

股份發行人及根據《上市規則》第十九B章上市的香港預託證券發行人的證券變動月報表 截至月份: 2026年1月31日 狀態: 新提交 致：香港交易及結算所有限公司 公司名稱: 堃博医疗控股有限公司 呈交日期: 2026年2月5日 I. 法定/註冊股本變動 | 1. 股份分類 | 普通股 | 股份類別 | 不適用 | | 於香港聯交所上市 (註1) | | 是 | | | | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | | 證券代號 (如上市) | 02216 | 說明 | | | | | | | | | | | 法定/註冊股份數目 | | | 面值 | | | 法定/註冊股本 | | | 上月底結存 | | | 2,000,000,000 | USD | | 0.000025 | USD | | 50,000 | | 增加 / 減少 (-) | | | 0 | | | | USD | | 0 | | 本月底結存 | | | 2,000,000,000 | USD | | 0.000025 | USD | | 50,000 | 本月底法定/ ...

Group 1 - The stock of Kunbo Medical-B (02216.HK) increased by nearly 10%, reaching a price of 2.65 HKD per share [2] - As of the report, the stock was up by 9.96% with a trading volume of 3.29 million HKD [2]

Core Viewpoint - Kubo Medical-B (02216) shares rose nearly 10%, currently up 9.96% at HKD 2.65, with a trading volume of HKD 3.29 million [1] Group 1: Product Development and Regulatory Approvals - Kubo Medical announced that its BroncTarget lung-targeted radiofrequency ablation system has entered the special review process for innovative medical devices by the National Medical Products Administration of China, indicating recognition of its core technology originality and clinical value [1] - The confirmatory clinical trials for the BroncTarget system are currently underway, with 28 hospitals across the country actively recruiting participants [1] Group 2: Market Expansion and Product Launches - Kubo Medical's self-developed BroncAblate intelligent lung radiofrequency ablation system has received registration approval from the Hong Kong Department of Health, marking its commercial launch in Hong Kong as the world's first natural orifice radiofrequency ablation device for lung cancer intervention [1] - Concurrently, the FleXNeedleCN single-use endoscopic aspiration biopsy needle has also been registered by the Hong Kong Department of Health [1] - The BroncTru single-use bronchial dilation catheter has successfully obtained approval from the Indonesian Ministry of Health, marking a new breakthrough in the Southeast Asian market [1]

Core Viewpoint - KPB Medical-B (02216) has seen a nearly 10% increase in stock price, currently trading at 2.65 HKD, following the announcement of significant regulatory advancements for its medical devices [1] Group 1: Regulatory Approvals - KPB Medical announced that its BroncTarget® lung-targeted radiofrequency ablation system has entered the special review process by the National Medical Products Administration (NMPA) in China, indicating recognition of its core technology and clinical value [1] - The BroncTarget® system is currently undergoing confirmatory clinical trials, with 28 hospitals across the country actively recruiting participants [1] Group 2: Product Launches - The BroncAblate® Smart® lung radiofrequency ablation system has received registration approval from the Hong Kong Department of Health, marking its commercial launch as the world's first natural orifice radiofrequency ablation device for lung cancer [1] - The FleXNeedleCN single-use endoscopic aspiration biopsy needle has also been registered with the Hong Kong Department of Health [1] - The BroncTru® single-use bronchial dilation catheter has successfully obtained approval from the Indonesian Ministry of Health, marking a new breakthrough in the Southeast Asian market [1]

Core Insights - The BroncTarget lung-targeted denervation radiofrequency ablation system has entered the special review process of the National Medical Products Administration (NMPA) in China, indicating recognition of its core technology originality and clinical significance [1] - Targeted Lung Denervation (TLD) is a breakthrough intervention technique for moderate to severe Chronic Obstructive Pulmonary Disease (COPD), aiming to suppress airway abnormal contraction and mucus hypersecretion [1] - The BroncTarget system employs innovative designs such as circular multi-electrodes, adjustable orifices, differentiated output of radiofrequency energy, real-time monitoring of temperature and impedance, and intelligent saline infusion to ensure ablation efficiency and safety [1] Clinical Trials - Confirmatory clinical trials for the BroncTarget system are currently underway, with 28 hospitals across the country actively recruiting participants [2]